O’Melveny Partners Geng Ke and Edwin Kwok Named to China’s “A-List” of Elite 100 LawyersJanuary 06, 2023
FOR IMMEDIATE RELEASE
BEIJING—January 6, 2023—Two O’Melveny partners, Geng Ke and Edwin Kwok, have been named among China’s 100 Elite Foreign Lawyers for 2022 on the “A-List” recently published by China Business Law Journal. This is the third consecutive year Geng Ke has been recognized for this award, and the inaugural appearance on the list for Edwin Kwok.
Managing partner of the firm’s Beijing office and a member of the firm’s Policy Committee, Geng Ke earned a J.D. from Northwestern University in 2003. Prior to becoming a lawyer, he earned a B.S. degree from Peking University and a Ph.D. in Biochemistry from New York University.
Ke is praised extensively in the report. Zhang Liang, the chief financial officer of Rainmed Medical, focuses on Ke's familiarity with the listing procedures of biotech companies in Hong Kong. An expert on both Hong Kong and US law, Ke led the team that helped Rainmed, a Suzhou-based vascular interventional robotics company, complete its H share IPO in July 2022. “Geng is a seasoned lawyer who has participated in the overseas listing of many Chinese pharmaceutical, medical and life science companies,” Zhang said. “His knowledge and experience are invaluable to biotech companies in China looking to go public.”
Joining Ke on the list is Hong Kong corporate and capital markets partner Edwin Kwok. Edwin frequently represents major investment banks, issuers in the healthcare industry, life sciences and biotech companies, Chinese SOEs, real estate and property management companies. He has extensive experience in the areas of IPOs, cross-border M&A, mergers and acquisitions, spin-offs, and follow-on equity and debt offerings. He is also highly experienced with privatization transactions of Hong Kong public companies.
In 2022, Ke Geng and Edwin Kwok led the O’Melveny capital markets team to complete nine Hong Kong IPOs. These transactions include representation of issuers such as Sipai Health Technology, 3D Medicines, Rainmed Medical, Cryofocus Medtech, Gaush Meditech, Jenscare Scientific, OrbusNeich, as well as underwriters in the Hong Kong IPO and listing of Huafang Group and Lushang Life Services, establishing O’Melveny’s position as the leader in the Hong Kong capital markets space. The O’Melveny team also led the going private transaction of China Vast Industrial Urban Development.
As for the methodology to select Geng Ke and Edwin Kwok to the list, China Business Law Journal conducted this annual survey of legal practitioners, in-house counsel and corporate management, and received thousands of nominations.
The full list of selectees may be found here.
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com, hear what our lawyers, staff and clients have to say in Our DNA video series, or learn more in our firm at-a-glance, annual report, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
O’Melveny & Myers LLP
+1 212 326 2218
O’Melveny & Myers LLP
+86 21 2307 7000